 Rohit Katial
Concepts (307)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 39 | 2023 | 2029 | 4.190 |
Why?
| | Anti-Asthmatic Agents | 13 | 2023 | 349 | 3.190 |
Why?
| | Aspirin | 11 | 2018 | 324 | 2.890 |
Why?
| | Hypersensitivity | 8 | 2018 | 252 | 2.760 |
Why?
| | Respiratory Tract Diseases | 6 | 2016 | 138 | 2.370 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2018 | 23 | 2.270 |
Why?
| | Rhinitis, Allergic, Seasonal | 8 | 2012 | 32 | 2.230 |
Why?
| | Sinusitis | 9 | 2022 | 174 | 1.910 |
Why?
| | Rhinitis | 6 | 2022 | 128 | 1.500 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 299 | 1.470 |
Why?
| | Nitric Oxide | 7 | 2018 | 823 | 1.420 |
Why?
| | Adrenal Cortex Hormones | 11 | 2022 | 497 | 1.300 |
Why?
| | Nasal Polyps | 6 | 2022 | 49 | 1.190 |
Why?
| | Histamine Antagonists | 4 | 2011 | 20 | 1.170 |
Why?
| | Eosinophils | 12 | 2023 | 278 | 1.080 |
Why?
| | Exhalation | 2 | 2018 | 35 | 1.020 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 41 | 1.010 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 117 | 0.980 |
Why?
| | Immunotherapy | 5 | 2017 | 474 | 0.970 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2016 | 61 | 0.930 |
Why?
| | Rhinitis, Allergic | 2 | 2014 | 35 | 0.890 |
Why?
| | Antibodies, Monoclonal, Humanized | 10 | 2023 | 663 | 0.770 |
Why?
| | Pancreatitis | 2 | 2012 | 107 | 0.750 |
Why?
| | Biomarkers | 7 | 2018 | 3408 | 0.710 |
Why?
| | Breath Tests | 4 | 2007 | 82 | 0.700 |
Why?
| | Androstadienes | 2 | 2010 | 97 | 0.690 |
Why?
| | Albuterol | 2 | 2010 | 102 | 0.680 |
Why?
| | Humans | 76 | 2023 | 114662 | 0.650 |
Why?
| | Drug Hypersensitivity | 3 | 2016 | 83 | 0.600 |
Why?
| | Bronchial Provocation Tests | 3 | 2018 | 51 | 0.600 |
Why?
| | Biological Products | 2 | 2018 | 166 | 0.560 |
Why?
| | Biological Therapy | 1 | 2017 | 26 | 0.550 |
Why?
| | STAT6 Transcription Factor | 1 | 2016 | 22 | 0.520 |
Why?
| | Insect Bites and Stings | 1 | 2016 | 13 | 0.520 |
Why?
| | Antibodies, Monoclonal | 3 | 2018 | 1262 | 0.510 |
Why?
| | Allergy and Immunology | 1 | 2016 | 51 | 0.500 |
Why?
| | Vaccination | 3 | 2012 | 1204 | 0.500 |
Why?
| | Administration, Intranasal | 6 | 2011 | 75 | 0.480 |
Why?
| | Sputum | 3 | 2013 | 285 | 0.470 |
Why?
| | Allergens | 5 | 2016 | 413 | 0.470 |
Why?
| | Practice Guidelines as Topic | 6 | 2017 | 1394 | 0.460 |
Why?
| | Anaphylaxis | 1 | 2016 | 143 | 0.430 |
Why?
| | Forced Expiratory Volume | 3 | 2018 | 475 | 0.430 |
Why?
| | Bronchial Hyperreactivity | 3 | 2018 | 95 | 0.390 |
Why?
| | Disease Progression | 5 | 2023 | 2380 | 0.390 |
Why?
| | Eosinophilia | 4 | 2019 | 186 | 0.370 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 25 | 0.350 |
Why?
| | Mast Cells | 2 | 2013 | 116 | 0.330 |
Why?
| | Acetates | 1 | 2010 | 95 | 0.330 |
Why?
| | Vaccines | 2 | 2004 | 375 | 0.330 |
Why?
| | Quinolines | 1 | 2010 | 129 | 0.320 |
Why?
| | Nose | 1 | 2009 | 55 | 0.320 |
Why?
| | Chronic Disease | 7 | 2022 | 1578 | 0.310 |
Why?
| | Double-Blind Method | 6 | 2023 | 1660 | 0.300 |
Why?
| | Laryngismus | 1 | 2008 | 6 | 0.300 |
Why?
| | Leukotriene E4 | 1 | 2008 | 27 | 0.300 |
Why?
| | Vocal Cords | 1 | 2008 | 25 | 0.300 |
Why?
| | Severity of Illness Index | 4 | 2017 | 2538 | 0.290 |
Why?
| | Adult | 23 | 2022 | 30544 | 0.280 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 182 | 0.280 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 66 | 0.270 |
Why?
| | Middle Aged | 20 | 2019 | 26733 | 0.270 |
Why?
| | T-Lymphocyte Subsets | 1 | 2009 | 383 | 0.270 |
Why?
| | Diagnosis, Differential | 4 | 2017 | 1342 | 0.270 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 339 | 0.260 |
Why?
| | Immunity, Cellular | 1 | 2007 | 248 | 0.260 |
Why?
| | Ethyl Chloride | 1 | 2005 | 1 | 0.260 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2011 | 119 | 0.250 |
Why?
| | Male | 25 | 2018 | 55583 | 0.250 |
Why?
| | Mastocytosis, Systemic | 1 | 2005 | 6 | 0.250 |
Why?
| | Skin Tests | 1 | 2005 | 116 | 0.240 |
Why?
| | Conjunctivitis, Allergic | 1 | 2004 | 3 | 0.240 |
Why?
| | Food Hypersensitivity | 2 | 2009 | 251 | 0.240 |
Why?
| | Female | 26 | 2022 | 59493 | 0.240 |
Why?
| | Anesthetics, Local | 1 | 2005 | 81 | 0.240 |
Why?
| | Syphilis | 1 | 2004 | 26 | 0.230 |
Why?
| | Analgesia | 1 | 2005 | 82 | 0.230 |
Why?
| | Serum Sickness | 1 | 2004 | 7 | 0.230 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2004 | 68 | 0.230 |
Why?
| | Bioterrorism | 1 | 2004 | 19 | 0.230 |
Why?
| | Bupropion | 1 | 2004 | 39 | 0.230 |
Why?
| | Exanthema | 1 | 2004 | 74 | 0.230 |
Why?
| | Signal Transduction | 2 | 2016 | 4512 | 0.220 |
Why?
| | Research Design | 1 | 2009 | 928 | 0.220 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2004 | 54 | 0.220 |
Why?
| | Administration, Inhalation | 3 | 2016 | 641 | 0.220 |
Why?
| | Cockroaches | 1 | 2003 | 21 | 0.220 |
Why?
| | Recurrence | 2 | 2017 | 935 | 0.220 |
Why?
| | Treatment Outcome | 9 | 2018 | 9088 | 0.210 |
Why?
| | Lolium | 1 | 2002 | 2 | 0.210 |
Why?
| | Alternaria | 1 | 2002 | 8 | 0.210 |
Why?
| | Clinical Trials as Topic | 4 | 2011 | 931 | 0.200 |
Why?
| | Pulmonary Atelectasis | 1 | 2002 | 11 | 0.200 |
Why?
| | Neisseria meningitidis | 1 | 2002 | 18 | 0.200 |
Why?
| | Poaceae | 1 | 2002 | 61 | 0.200 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 82 | 0.200 |
Why?
| | Young Adult | 9 | 2019 | 10466 | 0.190 |
Why?
| | Polysaccharides, Bacterial | 1 | 2002 | 66 | 0.190 |
Why?
| | Meningococcal Vaccines | 1 | 2002 | 48 | 0.190 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2002 | 58 | 0.190 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 124 | 0.190 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 26 | 0.190 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 112 | 0.190 |
Why?
| | United States | 5 | 2018 | 12181 | 0.190 |
Why?
| | Glycoproteins | 1 | 2002 | 304 | 0.180 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2010 | 12 | 0.180 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 239 | 0.170 |
Why?
| | Algorithms | 4 | 2020 | 1468 | 0.170 |
Why?
| | Respiratory Tract Infections | 1 | 2004 | 319 | 0.170 |
Why?
| | Adolescent | 10 | 2019 | 17841 | 0.170 |
Why?
| | Child | 8 | 2019 | 18412 | 0.170 |
Why?
| | Receptors, Leukotriene | 2 | 2016 | 13 | 0.170 |
Why?
| | Drug Combinations | 2 | 2010 | 287 | 0.160 |
Why?
| | Histamine | 2 | 2011 | 56 | 0.160 |
Why?
| | Cytokines | 2 | 2016 | 1840 | 0.160 |
Why?
| | STAT1 Transcription Factor | 2 | 2016 | 64 | 0.150 |
Why?
| | Bacterial Capsules | 2 | 2012 | 28 | 0.150 |
Why?
| | Aged | 6 | 2019 | 19069 | 0.150 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2018 | 29 | 0.150 |
Why?
| | Primary Health Care | 1 | 2008 | 1512 | 0.150 |
Why?
| | Immunoglobulin E | 3 | 2017 | 314 | 0.150 |
Why?
| | Aging | 1 | 2007 | 1618 | 0.150 |
Why?
| | Reference Values | 3 | 2007 | 743 | 0.140 |
Why?
| | Benzamides | 1 | 2018 | 169 | 0.140 |
Why?
| | Pyrroles | 1 | 2018 | 181 | 0.140 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 347 | 0.140 |
Why?
| | Quality of Life | 3 | 2014 | 2353 | 0.140 |
Why?
| | Leukotrienes | 1 | 2016 | 35 | 0.140 |
Why?
| | Interleukin-4 | 3 | 2013 | 206 | 0.130 |
Why?
| | Allergists | 1 | 2016 | 19 | 0.130 |
Why?
| | Venoms | 1 | 2016 | 30 | 0.130 |
Why?
| | Canada | 1 | 2017 | 322 | 0.130 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 38 | 0.130 |
Why?
| | Insecta | 1 | 2016 | 64 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 2 | 2012 | 447 | 0.120 |
Why?
| | Lung | 1 | 2007 | 3559 | 0.120 |
Why?
| | Drugs, Generic | 1 | 2015 | 18 | 0.120 |
Why?
| | Animals | 7 | 2017 | 31699 | 0.120 |
Why?
| | Epinephrine | 1 | 2016 | 163 | 0.120 |
Why?
| | Phosphorylation | 2 | 2016 | 1569 | 0.120 |
Why?
| | Drug Therapy, Combination | 2 | 2023 | 951 | 0.110 |
Why?
| | Basophils | 2 | 2013 | 64 | 0.110 |
Why?
| | T-Lymphocytes | 2 | 2016 | 1737 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2015 | 243 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2015 | 165 | 0.100 |
Why?
| | Drug Resistance | 1 | 2013 | 158 | 0.100 |
Why?
| | Olfaction Disorders | 1 | 2013 | 50 | 0.100 |
Why?
| | Salmonella Vaccines | 1 | 2012 | 1 | 0.100 |
Why?
| | Rabies Vaccines | 1 | 2012 | 2 | 0.100 |
Why?
| | Bacteriophage phi X 174 | 1 | 2012 | 4 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 668 | 0.100 |
Why?
| | Haemophilus Vaccines | 1 | 2012 | 27 | 0.100 |
Why?
| | Cost of Illness | 1 | 2014 | 254 | 0.100 |
Why?
| | Receptors, Histamine | 1 | 2011 | 5 | 0.100 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 25 | 0.100 |
Why?
| | Interleukins | 1 | 2013 | 236 | 0.100 |
Why?
| | Immunity, Humoral | 1 | 2012 | 112 | 0.100 |
Why?
| | History, 19th Century | 1 | 2011 | 54 | 0.100 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 131 | 0.090 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 251 | 0.090 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 41 | 0.090 |
Why?
| | Health Surveys | 2 | 2012 | 443 | 0.090 |
Why?
| | Fluticasone | 1 | 2010 | 87 | 0.090 |
Why?
| | Phenotype | 2 | 2017 | 2796 | 0.090 |
Why?
| | History, 20th Century | 1 | 2011 | 264 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2022 | 12546 | 0.090 |
Why?
| | Cyclopropanes | 1 | 2010 | 81 | 0.080 |
Why?
| | Clinical Competence | 1 | 2016 | 893 | 0.080 |
Why?
| | Receptors, IgG | 1 | 2009 | 67 | 0.080 |
Why?
| | Congresses as Topic | 1 | 2011 | 195 | 0.080 |
Why?
| | Medication Adherence | 1 | 2014 | 536 | 0.080 |
Why?
| | Chemokine CCL26 | 1 | 2009 | 7 | 0.080 |
Why?
| | Sulfides | 1 | 2010 | 94 | 0.080 |
Why?
| | Administration, Oral | 1 | 2011 | 728 | 0.080 |
Why?
| | Chemokines, CC | 1 | 2009 | 28 | 0.080 |
Why?
| | Bone Marrow | 2 | 2013 | 243 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2016 | 3003 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 66 | 0.080 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 172 | 0.080 |
Why?
| | Interleukin-13 | 1 | 2009 | 122 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2018 | 5045 | 0.070 |
Why?
| | Adenosine | 1 | 2009 | 203 | 0.070 |
Why?
| | Kartagener Syndrome | 1 | 2007 | 26 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2009 | 302 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 959 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 616 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 66 | 0.070 |
Why?
| | Health Status | 1 | 2012 | 722 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 448 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 498 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2009 | 770 | 0.060 |
Why?
| | Infant | 1 | 2018 | 7961 | 0.060 |
Why?
| | Flushing | 1 | 2005 | 1 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3345 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 911 | 0.060 |
Why?
| | Administration, Topical | 1 | 2005 | 138 | 0.060 |
Why?
| | Biomedical Research | 1 | 2011 | 585 | 0.060 |
Why?
| | Penicillin G | 1 | 2004 | 7 | 0.060 |
Why?
| | Child, Preschool | 1 | 2018 | 9114 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 28 | 0.060 |
Why?
| | Methylprednisolone Hemisuccinate | 1 | 2004 | 2 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1018 | 0.060 |
Why?
| | Arenaviruses, New World | 1 | 2004 | 3 | 0.060 |
Why?
| | Clostridium botulinum | 1 | 2004 | 4 | 0.060 |
Why?
| | Anthrax Vaccines | 1 | 2004 | 7 | 0.060 |
Why?
| | Diarrhea | 1 | 2005 | 171 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 22 | 0.060 |
Why?
| | Francisella tularensis | 1 | 2004 | 19 | 0.060 |
Why?
| | Placebos | 2 | 2018 | 197 | 0.060 |
Why?
| | Yersinia pestis | 1 | 2004 | 34 | 0.060 |
Why?
| | Headache | 1 | 2004 | 133 | 0.060 |
Why?
| | Bacterial Vaccines | 1 | 2004 | 61 | 0.060 |
Why?
| | Insect Control | 1 | 2003 | 11 | 0.060 |
Why?
| | Classification | 1 | 2003 | 19 | 0.050 |
Why?
| | Comorbidity | 2 | 2018 | 1448 | 0.050 |
Why?
| | Food Contamination | 1 | 2003 | 43 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 206 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2008 | 632 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 444 | 0.050 |
Why?
| | Disaster Planning | 1 | 2004 | 74 | 0.050 |
Why?
| | Viral Vaccines | 1 | 2004 | 88 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2003 | 55 | 0.050 |
Why?
| | Antigens, Dermatophagoides | 1 | 2002 | 10 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2013 | 6345 | 0.050 |
Why?
| | Insurance Claim Review | 1 | 2022 | 67 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 32 | 0.050 |
Why?
| | Consumer Product Safety | 1 | 2002 | 30 | 0.050 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2002 | 9 | 0.050 |
Why?
| | Menstruation | 1 | 2002 | 35 | 0.050 |
Why?
| | Drug Tolerance | 1 | 2002 | 79 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 2002 | 119 | 0.050 |
Why?
| | Plant Extracts | 1 | 2002 | 154 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 6115 | 0.040 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 364 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 913 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 797 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2478 | 0.040 |
Why?
| | Neutrophils | 2 | 2017 | 1176 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 5518 | 0.040 |
Why?
| | Gastroesophageal Reflux | 1 | 2002 | 234 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2285 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 433 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2010 | 4411 | 0.040 |
Why?
| | Bronchoconstrictor Agents | 1 | 2018 | 14 | 0.040 |
Why?
| | S-Nitrosoglutathione | 1 | 2018 | 6 | 0.040 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 955 | 0.040 |
Why?
| | Methacholine Chloride | 1 | 2018 | 47 | 0.040 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 7 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2018 | 47 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 522 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 124 | 0.040 |
Why?
| | Prognosis | 1 | 2005 | 3329 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4622 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 681 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2018 | 440 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 133 | 0.030 |
Why?
| | JC Virus | 1 | 2016 | 23 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1481 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2319 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2015 | 18 | 0.030 |
Why?
| | Biopsy | 2 | 2011 | 1036 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2015 | 25 | 0.030 |
Why?
| | Risk Factors | 1 | 2008 | 8632 | 0.030 |
Why?
| | Nebulizers and Vaporizers | 1 | 2015 | 78 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 696 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 143 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 405 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 337 | 0.030 |
Why?
| | Receptors, Interleukin-5 | 1 | 2013 | 5 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 17 | 0.030 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 46 | 0.030 |
Why?
| | Equipment Design | 1 | 2015 | 508 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 723 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 560 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2013 | 116 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2013 | 293 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 313 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2016 | 719 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 6219 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2011 | 78 | 0.020 |
Why?
| | Efficiency | 1 | 2012 | 84 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2011 | 93 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2010 | 9 | 0.020 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2010 | 4 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 49 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 396 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 134 | 0.020 |
Why?
| | Occupational Health | 1 | 2012 | 165 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 303 | 0.020 |
Why?
| | Cats | 1 | 2009 | 193 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 2710 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 258 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 233 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 362 | 0.020 |
Why?
| | Emotions | 1 | 2012 | 472 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 544 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 807 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1226 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 676 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 3885 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1842 | 0.020 |
Why?
| | Brain | 1 | 2016 | 2371 | 0.010 |
Why?
| | ROC Curve | 1 | 2005 | 442 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4692 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2362 | 0.010 |
Why?
| | Mice | 1 | 2013 | 14863 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2005 | 4408 | 0.010 |
Why?
|
|
Katial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|